drugset / Trial / NCT00758680
A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED)
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will asses the safety, tolerability, multiple-dose pharmacokinetics and pharmacodynamics of MK1006 in participants with type 2 diabetes.
Timeline
- Start
- 2008-08
- Primary completion
- 2010-03
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-1006 | Unknown | 20 mg | Oral |
| Subject | MK-1006 | Unknown | 30 mg | Oral |
| Subject | MK-1006 | Unknown | 40 mg | Oral |
| Subject | MK-1006 | Unknown | 50 mg | Oral |
| Subject | MK-1006 | Unknown | 80 mg | Oral |
| Subject | MK-1006 | Unknown | 120 mg | Oral |